TAGRISSO® (Osimertinib)

The FDA on February 16, 2024, approved TAGRISSO® with platinum-based chemotherapy for patients with Locally advanced or metastatic Non-Small Cell Lung Cancer (La/mNSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. TAGRISSO® is a product of AstraZeneca Pharmaceuticals LP.